申请人:AVISTA PHARMA SOLUTIONS INC
公开号:WO2020160075A1
公开(公告)日:2020-08-06
The present disclosure describes novel compounds, or their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their medical uses. The compounds of the disclosure have activity as prostaglandin EP4 receptor antagonists, and are useful in the treatment or alleviation of pain and inflammation and other inflammation-associated disorders, such as arthritis, treating or preventing disorders or medical conditions selected from pain, inflammatory diseases and the like. Also described herein are methods of treating pain by administering the compounds of the disclosure, which are EP4 receptor antagonists.
本公开描述了新颖化合物或其药用盐、含有它们的药物组合物以及它们的医药用途。本公开的化合物具有前列腺素EP4受体拮抗剂的活性,并且在治疗或缓解疼痛和炎症以及其他与炎症相关的疾病,如关节炎,治疗或预防疼痛、炎症性疾病等疾病或医疗状况方面具有用处。本文还描述了通过给予本公开的化合物(即EP4受体拮抗剂)来治疗疼痛的方法。